Last updated: 2026-09-09 19:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Fortrea Holdings Inc. (FTRE) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $16.88, with a market capitalisation of $1.68B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.31 to $21.39. This page covers its latest market performance, valuation, price trends and company information.
$1.68B | |
$16.97 | |
$41.02 | |
$3.97 | |
$17.06 | |
664.67K | |
1.41M | |
-- | |
$21.39 | |
$8.31 | |
-- | |
-- |
Fortrea Holdings Inc. (FTRE) is currently trading at $16.88 as of 2026-09-09 19:02:27, down 1.05% ($0.18) from the previous close of $17.06
During today's regular trading session, FTRE has traded between $3.97 and $41.02, with a trading volume of 664.67K shares. The current price is near the middle of today's range.
Over the past seven days, Fortrea Holdings Inc. (FTRE) moved from $18.81 to $16.88, representing a decline of 10.26% ($1.93).
The stock traded between $16.72 and $19.14 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.11 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 65.5%
FTRE is currently trading at $16.88, placing it 65.5% of the way from its 52-week low of $8.31 to its 52-week high of $21.39. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 14000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fortrea Holdings Inc. (FTRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.